Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Paxil Table · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Paroxetine hydrochloride 40 mg tablet |
| 2 | ACTIVE_COMPARATOR | Paxil® 40 mg Table |
| Name | Type | Description |
|---|---|---|
| Paroxetine hydrochloride 40 mg tablet | DRUG | 40mg, single dose fasting |
| Paxil® 40 mg Table | DRUG | 40mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or female of non-childbearing potential. 1. Women will not be considered of childbearing potential if one of the following is reported and documented on the medical history: 1. postmenopausal with an absence of menses for a...
Paxil Table is a small molecule drug being studied in healthy volunteers. It is a paroxetine hydrochloride tablet formulation, and the clinical trial for it was conducted in healthy participants to assess the product. The drug is currently in early Phase 1 clinical development.
Paxil Table is being developed by Viatris Inc., a pharmaceutical company traded on the NASDAQ under the ticker symbol VTRS. The company is conducting clinical research on this paroxetine hydrochloride tablet formulation.
Paxil Table is in early Phase 1 clinical development. The single clinical trial for this drug was classified as an early Phase 1 study and has been completed. The drug is investigational and has not been approved by regulatory authorities.
Paxil Table has one completed clinical trial registered under NCT00648193, titled "Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg." This early Phase 1 study enrolled 36 healthy volunteers in the United States and was active-controlled.
Paxil Table is a formulation of paroxetine hydrochloride. The clinical trial compared paroxetine hydrochloride tablets 40 mg to Paxil® tablets 40 mg, indicating that Paxil Table is a generic or alternative version of the branded product Paxil.